Latest News & Updates

Pathios Therapeutics Announces Promising Clinical Progress for First-in-Class GPR65 Antagonist PTT-4256 at ASCO 2026

OXFORD, UK - 5 June, 2026 High-quality biomarker data confirms successful GPR65 target engagement and intratumoral immune activation Dose-proportional pharmacokinetic profile validates the viability of patient-friendly, once-daily oral dosing Early...

Pathios Published in Cancers 2026, A Novel Approach in Renal Cell Carcinoma

OXFORD, UK - 16 December, 2025 - Pathios, in collaboration with Weatherden, was recently featured in Cancers 2026 with a review examining the role of GPR65 in renal cell carcinoma...

Pathios Therapeutics Unveils First Public Clinical Data for First-in-Class GPR65 Antagonist PTT-4256 at SITC 2025

OXFORD, UK - 11 November, 2025 First-in-human RAISIC-1 trial demonstrates favourable safety and tolerability profile across four dose levels with zero dose-limiting toxicities (DLTs) Early clinical benefit achieved, with four...

Pathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive Director

OXFORD, UK – September 24, 2025 – Pathios Therapeutics Limited (“Pathios”), a biotech company advancing the first clinical GPR65 antagonist program in cancer, today announced that Jon Wigginton, M.D., has...

Pathios Therapeutics Appoints Sumeet Ambarkhane, M.D., as Chief Medical Officer

OXFORD, UK – March 24, 2025 – Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced the appointment of Sumeet Ambarkhane,...

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers

MELBOURNE, AUSTRALIA and OXFORD, UK – November 20, 2024 Pathios Therapeutics (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced dosing of the first...

Pathios Therapeutics Appoints Paul G. Higham as Chief Executive Officer as Company Prepares to Enter the Clinic

Pathios today announced the appointment of experienced biotechnology industry executive, Paul G. Higham, as Chief Executive Officer (CEO). He brings over 20 years of C-level executive biotechnology company experience to...

Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic

Pathios has raised USD $25 million in the first close of a Series B financing. The financing consists of a new strategic investment from Bristol Myers Squibb, as well as...

1 2 3 Next »

Cookie	Duration	Description
_GRECAPTCHA	6 months	Google reCAPTCHA sets a necessary cookie (_GRECAPTCHA) when executed for the purpose of providing its risk analysis.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Advertisement" category.
cookielawinfo-checkbox-analytics	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
rc::a	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::b	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::f	session	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
wordpress_[hash] (Admin only)	session	Used to store the authentication details on login. The authentication details include the username and double hashed copy of the password. However, this usage of the cookie is limited to the admin console area, the backend dashboard of the website.
wordpress_logged_in_XXX	session	WordPress uses this cookie to indicate when you’re logged in, and who you are, for most interface use.

Cookie	Duration	Description
-settings-1, wp-settings-time-1	1 year	WordPress uses this cookie to customize your view of admin interface, and possibly also the main site interface.
VISITOR_INFO1_LIVE	6 months	YouTube sets this cookie to measure bandwidth, determining whether the user gets the new or old player interface.
VISITOR_PRIVACY_METADATA	6 months	This cookie is used to store the user's consent and privacy choices for their interaction with the site. It records data on the visitor's consent regarding various privacy policies and settings, ensuring that their preferences are honored in future sessions.
YSC	6 months	This cookie is set by YouTube to track views of embedded videos.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.